BeyondSpring (NASDAQ:BYSI) Issues Earnings Results, Beats Estimates By $1.78 EPS

BeyondSpring (NASDAQ:BYSI) released its earnings results on Friday. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $1.78, FiscalAI reports.

BeyondSpring Price Performance

NASDAQ:BYSI traded up $0.00 during trading hours on Friday, reaching $0.60. 33,174 shares of the company were exchanged, compared to its average volume of 278,819. The business has a 50 day moving average of $0.66 and a 200 day moving average of $1.23. BeyondSpring has a 1-year low of $0.42 and a 1-year high of $2.44. The company has a market capitalization of $24.72 million, a P/E ratio of -5.01 and a beta of -0.12.

Analyst Ratings Changes

Separately, Weiss Ratings raised BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About BeyondSpring

BeyondSpring Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects. Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.